OB Grand Rounds Calendar

Back to Listing

INFORMATIONAL ONLY (NO CME): Uterine Fibroids: Overview and Update on ACOG guidelines, including trial data of Myfembree (relugolix/ethinyl estradiol/NETA)

Event Type
Informational
Sponsor
Pfizer Inc.
Virtual
wifi event
Date
Jul 21, 2022   8:00 - 9:00 am  
Speaker
Mark Juhn, D.O. and Katie Tellor, PharmD, FACC, BCPS
Contact
David Haney
E-Mail
dhaney@uic.edu
Phone
309-655-3024
Views
3

PLEASE NOTE: This event is informational only and not part of the routine OB/GYN Department Grand Rounds. As such, no CME will be provided by attending.

"Uterine Fibroids: Overview and Update on ACOG guidelines, including trial data of Myfembree (relugolix/ethinyl estradiol/NETA)," will provide a brief overview of selected patient-reported outcome measures.

Objectives:

  1. Provide a brief overview of uterine fibroid epidemiology and demographics (Dr. Juhn).
  2. Provide a simplified, tabular format of ACOG 2021 guidelines for management of uterine fibroids (Dr. Juhn).
  3. Review the two pivotal clinical trial data of Myfembree (relugolix/ethinyl estradiol/NETA) which led to FDA approval (Dr. Juhn).
  4. Provide a high-level overview of selected patient reported outcomes measures (PROMs) in uterine fibroids (Dr. Tellor).

Presenters:

Mark Juhn, D.O.
Sr. Director, Field Medical Director
Women’s Health and Metabolism
Pfizer Inc.

Katie Tellor, PharmD, FACC, BCPS
Director, Internal Medicine Field Medical Outcomes & Analytics
Pfizer Inc.

link for robots only